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Definition  
• Systemic connective tissue diseases (systemic 
autoimmune diseases, collagen diseases, collagen 
vascular diseases , SCTD) refer  to a group of chronic 
autoimmune inflammatory disorders involving the 
protein-rich connective tissue that supports organs and 
other parts of the body, first of all the joints, muscles, 
skin, and other organs and organ systems, including 
the eyes, heart, lungs, kidneys, gastrointestinal tract, 
and blood vessels. 
• There are more than 200 disorders that affect the 
connective tissue.  
http://www.webmd.com/a-to-z-guides/connective-tissue-disease 
Classification  
 
Heritable SCTD 
• Marfan syndrome   
• Peyronie's disease   
• Ehlers-Danlos syndrome    
•  Osteogenesis imperfecta   
• Stickler syndrome   
• Alport syndrome   
• Congenital contractural 
arachnodactyly   
• Loeys–Dietz syndrome   
Acquired SCTD 
• Systemic lupus 
erythematosus (SLE) 
• Rheumatoid arthritis   
• Sjögren syndrome   
• Psoriatic arthritis 
• Dermatomyositis (DM) 
• Polymyositis (PM) 
• Anti-synthetase syndrome  
• Mixed connective tissue 
disease  
• Scurvy   
https://en.wikipedia.org/wiki/Connective_tissue_disease 
Mechanisms   
(The Connective Tissues Abnormalities)  
http://rheumatology.oxfordjournals.org/content/45/suppl_3/iii1.full http://emedicine.medscape.com/article/335815-overview#a4 
• SCTD have the connective tissues of the body as a target of 
chronic autoimmune progressive inflammation.  
• However, the mechanisms of SCTD are diverse, the connective 
tissues abnormalities include impaired angiogenesis as well as 
immunological alterations, e.g. B-lymphocytes and T-
lymphocytes activation , self-antigens apoptotic modification 
and immune response against them, widespread lymphocytic 
and plasmacytic infiltration, activation of Toll-like receptors, 
etc. with abundant fibrinoid deposits.  
• SCTD characterized by varying tissue distribution with different 
pattern of organ involvement. 
Mechanisms   
(Body Systems Affected by SCTD)  
http://www.lifeextension.com/~/media/lef/images/magazine/mag2014/images/mar2014_smad_05.ashx 
Mechanisms    
(Different Diseases associated with Specific 
Autoantibodies) 
Disease 
• Systemic Lupus Erythematosus  
• Rheumatoid Arthritis  
• Sjögren Syndrome Systemic 
Sclerosis 
• Polymyositis/Dermatomyositis 
Mixed Connective Tissue Disease  
• Wegener’s Granulomatosus 
Autoantibody 
• Anti-dsDNA, Anti-SM  
• RF, Anti-RA33 
• Anti-Ro(SS-A),Anti-La(SS-B)  
• Anti-Scl-70, Anti-centromere  
• Anti-Jo-1  
• Anti-U1-RNP 
• c-ANCA 
 
rheumatology.oxfordjournals.org/content/45/suppl_3/iii1.full 
Diagnosis 
(Connective Tissue Disease Cascade (CTDC)) 
  
https://en.wikipe http://www.mayomedicallaboratories.com/it-mmfiles/Connective_Tissue_Disease_Cascade__CTDC_.pdf dia.org/wiki/Rheumatoid_arthritis#Signs_and_symptoms 
Marfan syndrome 
(Definition) 
• Marfan syndrome (MFS) is a spectrum of 
disorders caused by a heritable genetic 
defect of connective tissue that has an 
autosomal dominant mode of 
transmission. 
• The defect itself has been isolated to 
the FBN1gene on chromosome 15, which 
codes for the connective tissue protein 
fibrillin. 
• Abnormalities in fibrillin cause a myriad of 
distinct clinical problems, of which the 
musculoskeletal, cardiac, and ocular 
system. 
https://stottilien.files.wordpress.com/2014/01/echnaton.png https://en.wikipedia.org/wiki/Marfan_syndrome rheumatology.oxfordjournals.org/content/45/suppl_3/iii1.full 
Pharaoh Akhenaton 
Marfan syndrome 
(External Signs) 
www.somospacientes.com/wp-content/uploads/2013/04/S%C3%ADndrome-de-Marfan.jpg mayoclinic.org/diseases-conditions/marfan-syndrome/symptoms-causes/dxc-20195415 
a) the Steinberg sign  
b) the Walker-Murdoch sign 
Marfan syndrome 
(Pectus Carinatum Deformity) 
http://www.londonorthotics.co.uk/media/22949/pectuse-cs1-before_boxpromo.jpg 
Pectus 
carinatum also called 
pigeon chest, is 
adeformity of the 
chest characterized 
by a protrusion of 
the sternum and 
ribs. 
Marfan syndrome 
(Dural Ectasia) 
http://www.neurology.org/content/71/17/1378/F1.expansion.html 
T1- and T2-weighted sagittal MR images of the lumbar spine reveal 
enlargement of the thecal sac (yellow arrow) with mild scalloping of the 
lumbar vertebral bodies and marked focal thinning of the sacrum (white 
arrow). An enlarged flow void anterior to the spine (red arrow) is related to 
dilation of the descending aorta 
Marfan syndrome 
(Echocardiography) 
http://circ.ahajournals.org/content/117/21/2802#T1 
A) Two-dimensional echo image in the 
parasternal long axis demonstrates dilation 
of the aortic root in a MFS patient.  
B) Color Doppler echo shows mild 
regurgitation through an otherwise normal 
aortic valve, which results from the 
dilatation of the root.  
C) MFS patient with moderate mitral valve 
prolapse, demonstrated in 2-dimensional 
echo images.  
D) Classic M-mode demonstration of prolapse 
of the posterior mitral valve leaflet (arrow). 
Marfan syndrome 
(Computed tomography) 
http://circ.ahajournals.org/content/117/21/2802#T1 
• A) Volume-rendered computed tomographic angiography 
image demonstrates the dilatation of the proximal aortic 
root and ascending aorta.  
• B and C) Computed tomographic imaging demonstrates 
evidence of acute type A dissection (arrows). 
Marfan syndrome 
(Ectopia Lentis) 
http://www.aapos.org/terms/conditions/68 
• Ectopia lentis is a shift in the 
location of the lens inside the 
eye.  
• The lens moves from its 
centered location in the eye so 
that the person is not looking 
through the center of their 
lens.   
• This dislocation is caused by 
weakness in the connective 
tissue that holds the lens in 
place (zonules).  
retroillumination 
Marfan syndrome 
(Diagnostic Criteria) 
• The diagnosis of MFS relies on a set of defined clinical criteria 
(the Ghent nosology) revised in 2010.   
• The criteria puts more weight on the cardiovascular 
manifestations of the disorder.  
• Aortic root aneurysm and ectopia lentis (dislocated lenses) are 
now cardinal features. 
• In the absence of any family history, the presence of these two 
features is sufficient for the unequivocal diagnosis of Marfan 
syndrome. 
• In the absence of one of these two cardinal features, the 
presence of an FBN1 mutation of positive systemic score is 
required.  
 
http://jmg.bmj.com/content/47/7/476.abstract 
Marfan syndrome 
(Diagnostic Criteria: In the Absence of Family History) 
• Aortic Root Dilatation Z score ≥ 2 AND Ectopia Lentis = Marfan 
syndrome   
• Aortic Root Dilatation Z score ≥ 2 AND FBN1 = Marfan syndrome   
• Aortic Root Dilatation Z score ≥ 2 AND Systemic Score ≥ 7pts = 
Marfan   
• Ectopia lentis AND FBN1 with known Aortic Root Dilatation = 
Marfan syndrome   
http://jmg.bmj.com/content/47/7/476.abstract 
Marfan syndrome 
(Diagnostic Criteria: In the Presence of Family History) 
• Ectopia lentis AND Family History of Marfan syndrome (as 
defined above) = Marfan syndrome   
• A systemic score ≥ 7 points AND Family History of Marfan 
syndrome (as defined above) = Marfan   
• Aortic Root Dilatation Z score ≥ 2 above 20 yrs. old, ≥ 3 below 
20 yrs. old) + Family History of Marfan syndrome (as defined 
above) = Marfan syndrome   
http://jmg.bmj.com/content/47/7/476.abstract 
Marfan syndrome 
(Diagnostic Criteria: Points for Systemic Score) 
• Wrist AND thumb sign = 3 (wrist OR 
thumb sign = 1) 
• Pectus carinatum deformity = 2 
(pectus excavatum or chest asymmetry 
= 1) 
• Hindfoot deformity = 2 (plain pes 
planus = 1) 
• Dural ectasia = 2 
• Protrusio acetabuli = 2 
• pneumothorax = 2  
• Reduced upper segment/lower 
segment ratio AND increased 
arm/height AND no severe scoliosis = 1 
 
http://jmg.bmj.com/content/47/7/476.abstract 
• Scoliosis or 
thoracolumbar kyphosis = 1 
• Reduced elbow extension = 1 
• Facial features (3/5) = 1 
(dolichocephaly, enophthalmos, 
downslanting palpebral fissures, 
malar hypoplasia, retrognathia) 
• Skin striae (stretch marks) = 1 
• Myopia > 3 diopters = 1 
• Mitral valve prolapse 1⁄4 1 
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Marfan syndrome 
(Physical activity) 
• Probably permissible activities: bowling, golf, skating (but not 
ice hockey), snorkeling, brisk walking, treadmill, stationary 
biking, modest hiking, and doubles tennis. 
• Intermediate risk: basketball (both full and half-court), 
racquetball, squash, running (sprinting and jogging), skiing 
(downhill and cross-country), soccer, singles tennis, touch (flag) 
football, baseball, softball, biking, lap swimming, motorcycling, 
and horseback riding. 
• High risk: body building, weightlifting (non-free and free 
weights), ice hockey, rock climbing, windsurfing, surfing, and 
scuba diving. 
https://en.wikipedia.org/wiki/Marfan_syndrome#Management 
Marfan syndrome 
(Management) 
• Although future therapy directed at the fibrillin-1 gene or the TGF-β axis 
may ultimately prove most effective at preventing the aortic complications 
of MFS , β-blocker therapy currently remains the “standard of care”  or if not 
tolerated calcium channel blockers, angiotensin converting enzyme  
• (ACE) inhibitors or  angiotensin II receptor antagonists (ARBs) can be use. 
• Management of type A acute dissection of the aorta is a surgical 
emergency.  
• The initial management patients with type B acute dissection of the aorta 
can employ standard medical approaches. 
• Surgical repair of the severely regurgitant mitral valve is possible. 
• In end-stage heart failure, orthotopic transplantation is an effective 
approach. 
• Any spinal surgery should only follow detailed imaging and careful surgical 
planning. 
 
 http://emedicine.medscape.com/article/946315-overview http://circ.ahajournals.org/content/117/21/2802#T1 
Systemic Lupus Erythematosus 
(Definition) 
• Systemic lupus erythematosus (SLE), also known simply 
as lupus,  is a chronic autoimmune inflammatory disease that 
has protean manifestations and follows a relapsing and 
remitting course.   
• Common symptoms include painful and swollen 
joints, fever, chest pain, hair loss, mouth ulcers, swollen lymph 
nodes, feeling tired, and a red rash which is most commonly on 
the face.  
• More than 90% of cases of SLE occur in women, frequently 
starting at childbearing age.  
http://emedicine.medscape.com/article/332244-overview https://en.wikipedia.org/wiki/Systemic_lupus_erythematosus 
Systemic Lupus Erythematosus 
(Manifestations) 
• Constitutional (e.g., fatigue, fever, arthralgia, weight changes). 
• Musculoskeletal (e.g., arthralgia, arthropathy, myalgia, frank 
arthritis, avascular necrosis). 
• Dermatologic (e.g., malar rash, photosensitivity, discoid lupus). 
• Renal (e.g., acute or chronic renal failure, acute nephritic 
disease). 
• Neuropsychiatric (e.g., seizure, psychosis). 
• Pulmonary (e.g., pleurisy, pleural effusion, pneumonitis, 
pulmonary hypertension, interstitial lung disease). 
• Gastrointestinal (e.g., nausea, dyspepsia, abdominal pain). 
• Cardiac (e.g., pericarditis, myocarditis). 
• Hematologic (e.g., cytopenias such as leukopenia, lymphopenia, 
anemia, or thrombocytopenia). 
http://emedicine.medscape.com/article/332244-overview#showall 
Systemic Lupus Erythematosus 
(Most Common Symptoms) 
https://en.wikipedia.org/wiki/Systemic_lupus_erythematosus 
Systemic Lupus Erythematosus 
(Malar Rash) 
The first criterion of SLE is a 
malar rash, also called butterfly 
rash, characterized by an 
erythema over the cheeks and 
nasal bridge (but sparing the 
nasolabial folds).  
It lasts from days to weeks and 
is occasionally painful or 
pruritic. 
http://2.bp.blogspot.com/-KB_jTj2IeVQ/U_6ePJ0Ll6I/AAAAAAAAAHU/t82ZVnCnxgQ/s1600/malar%20rash%20image.JPG 
Systemic Lupus Erythematosus 
(Photosensivity) 
Photosensitive SLE rashes typically occur on the face or extremities, 
which are sun-exposed regions. Although the interphalangeal spaces are 
affected, the metacarpophalangeal (MCP) and proximal interphalangeal 
(PIP) and distal interphalangeal (DIP) joints are spared.  
http://emedicine.medscape.com/article/332244-overview 
Systemic Lupus Erythematosus 
(Discoid Rash) 
• Discoid rashes are usually slightly elevated red or pink areas that form 
flakes or a crust on the surface of the skin and are rarely found below 
the chin, occurring most often on the scalp, and outer ear, and almost 
never on the legs.    
• Rashes may be itchy and get larger, spreading outward and then leaving 
a central scar.  In individuals with darker complexions, the central area 
can become de-pigmented; in all individuals the outer red area may 
become hyper-pigmented. 
http://diseasesdefinition.com/wp-content/uploads/2014/12/Discoid-Lupus-Erythematosus.jpg 
Systemic Lupus Erythematosus 
(Oral Ulcers) 
A 30-year-old male with systemic lupus erythematosus 
presented a palatal ulcer typical for lupus. 
http://www.tannlegetidende.no/image/2015/F15-02-008.jpg 
Systemic Lupus Erythematosus 
(Serositis) 
Serositis refers to inflammation of the serous tissues of the body, 
the tissues lining the lungs (pleura), heart (pericardium), and the 
inner lining of the abdomen (peritoneum) and organs within. 
http://journal.publications.chestnet.org/article.aspx?articleid=1211826 
Systemic Lupus Erythematosus 
(Renal Disorder ) 
Glomerular disease with SLE is common, and lupus nephritis 
can have many morphologic manifestations as seen on renal 
biopsy. 
http://library.med.utah.edu/WebPath/RENAHTML/RENAL120.html 
Systemic Lupus Erythematosus 
(Laboratory Tests) 
• Antinuclear antibody (ANA) testing and anti-extractable nuclear antigen 
(anti-ENA) form the mainstay of serologic testing for SLE, although ANA 
screening yields positive results in many connective tissue disorders and 
other autoimmune diseases, and may occur in normal individuals.  
• Subtypes of antinuclear antibodies include anti-Smith and anti-double 
stranded DNA (dsDNA) antibodies (which are linked to SLE) and anti-histone 
antibodies (which are linked to drug-induced lupus); anti-dsDNA antibodies 
are highly specific for SLE. 
•  Other tests routinely performed in suspected SLE are complement 
system levels (low levels suggest consumption by the immune 
system), electrolytes and kidney function (disturbed if the kidney is 
involved), liver enzymes, and complete blood count. 
• The  lupus erythematosus  (LE) cells are only found in 50–75% of SLE cases, 
and they are also found in some people with rheumatoid arthritis, 
scleroderma, and drug sensitivities.  
https://en.wikipedia.org/wiki/Systemic_lupus_erythematosus#Diagnosis 
Systemic Lupus Erythematosus 
(The American College of Rheumatology Revised 
Classification) 
http://www.eular.org/myuploaddata/files/sample%20chapter20_mod%2017.pdf 
Systemic Lupus Erythematosus 
(the European League Against Rheumatism (EULAR) 
released recommendations for the treatment of SLE) 
• In patients without major organ manifestations, glucocorticoids 
and antimalarial agents may be beneficial. 
• NSAIDs may be used for short periods in patients at low risk for 
complications from these drugs.  
• Consider immunosuppressive agents (e.g., azathioprine, 
mycophenolate mofetil, methotrexate) in refractory cases or 
when steroid doses cannot be reduced to levels for long-term 
use.   
http://emedicine.medscape.com/article/332244-overview#showall 
Systemic Lupus Erythematosus 
(Medications) 
• Biologic disease-modifying antirheumatic drugs (DMARDs): 
belimumab, rituximab, IV immune globulin. 
• Nonbiologic DMARDS: cyclophosphamide, methotrexate, 
azathioprine, mycophenolate, cyclosporine. 
• Nonsteroidal anti-inflammatory drugs (NSAIDS): e.g., ibuprofen, 
naproxen, diclofenac. 
• Corticosteroids: e.g., methylprednisolone, prednisone 
• Antimalarials: e.g., hydroxychloroquine. 
http://emedicine.medscape.com/article/332244-overview#showall 
Systemic Lupus Erythematosus 
(Adjunctive therapies) 
• No diet-based treatment has been proven effective.  
• Patients should be reminded that activity may need to be 
modified as tolerated.  
• Stress and physical illness may precipitate SLE flares.  
• Persons with SLE should wear sunscreen and protective clothing 
or avoid sun exposure to limit photosensitive rash or disease 
flares. 
• Vitamin D supplementation may improve endothelial function.  
http://emedicine.medscape.com/article/332244-overview#showall 
Systemic Lupus Erythematosus 
(Multisystemic Approach) 
• Rheumatologist. 
• Infectious disease specialist. 
• Neurologist. 
• Pulmonologist. 
• Cardiologist. 
• Gastroenterologist. 
• Nephrologist. 
• Dermatologist. 
• Hematologist. 
• High-risk obstetrician. 
http://emedicine.medscape.com/article/332244-overview#showall 
Scleroderma    
(Definition) 
• Scleroderma (systemic sclerosis (SSc)) is a rare chronic disease 
of unknown cause characterized by diffuse fibrosis, 
degenerative changes, and vascular abnormalities in the skin, 
joints, and internal organs (especially the esophagus, lower GI 
tract, lungs, heart, and kidneys) .  
• Common symptoms include Raynaud phenomenon, 
polyarthralgia, dysphagia, heartburn, and swelling and 
eventually skin tightening and contractures of the fingers.  
• Lung, heart, and kidney involvement accounts for most deaths.   
http://www.merckmanuals.com/professional/musculoskeletal-and-connective-tissue-disorders/autoimmune-rheumatic-disorders/systemic-sclerosis 
Scleroderma    
(Manifestations) 
• Skin and nail manifestations (swelling of the skin, telangiectasias, 
sclerodactyly, masklike face, subcutaneous calcifications, digital 
ulcers). 
• Joint manifestations (polyarthritis, flexion contractures in the 
fingers, wrists, and elbows, etc.). 
• Gastrointestinal (GI)manifestations (dysphagia, malabsorption, 
pneumatosis intestinalis, peritonitis, and biliary cirrhosis). 
• Cardiopulmonary manifestations (lung fibrosis, leading to 
restrictive disease with eventual respiratory failure, pulmonary 
hypertension, heart failure, pericarditis, and heart arrhythmias). 
• Renal manifestations (severe renal disease, usually heralded by 
sudden, severe hypertension with features of thrombotic 
microangiopathic hemolytic anemia). 
http://www.merckmanuals.com/professional/musculoskeletal-and-connective-tissue-disorders/autoimmune-rheumatic-disorders/systemic-sclerosis 
Scleroderma    
(Sclerodactyly) 
http://images.slideplayer.com/32/10064496/slides/slide_60.jpg 
Scleroderma    
(Masklike Face) 
http://www.ijdvl.com/articles/2013/79/3/images/ijdvl_2013_79_3_439_110801_f5.jpg 
Scleroderma    
(Subcutaneous Calcifications) 
http://www.pcds.org.uk/ee/images/made/ee/images/uploads/clinical/calcificacion06CREST_600_450_70_http:www.pcds.org.ukeeassetsimgwatermark.gif_0_0_80_r_b_-5_-5_.jpg 
Scleroderma    
(Digital Ulcers) 
http://what-when-how.com/wp-content/uploads/2012/04/tmpE87_thumb222.jpg 
Scleroderma    
(Flexion Contractures In The Fingers) 
https://handlab.com/resources/wp-content/uploads/2014/04/CP2-1.jpg 
Scleroderma    
(2013  ECR/EULAR Criteria) 
http://www.rheumtutor.com/2013-acreular-classification-criteria-for-scleroderma/ 
Scleroderma    
(Early Diagnosis - the VEDOSS Initiative) 
The VEDOSS (Very Early Diagnosis Of Systemic Sclerosis) initiative in 
Europe identified the following features as being key to diagnosing 
scleroderma in the very early stage: 
• Antinuclear antibodies. 
• Scleroderma-specific antibodies. 
• Scleroderma pattern on nailfold capillaroscopy. 
• Puffy fingers in Raynaud's syndrome patients. 
http://patient.info/doctor/systemic-sclerosis-scleroderma 
Scleroderma    
(Management) 
• There is no cure for scleroderma, and management consists of controlling 
symptoms and preventing complications. 
• Non-selective immunosuppressive cyclophosphamide has been associated 
with improvements in both pulmonary function and skin involvement but 
efficacy may reduce beyond two years.  
• Mycophenolate mofetil has also been used with improvements in lung 
function.  
• Azathioprine and methotrexate alone may not be as beneficial but have been 
shown to be effective for skin involvement. 
• T-cell targeted therapy which is being tested includes sirolimus, 
antithymocyte globulin, and basiliximab. 
• Oral corticosteroids. 
•  Nifedipine, nitroglycerin, phosphodiesterase type 5 inhibitors, prostaglandins 
are the drugs for Raynaud's phenomenon. 
• In all other cases symptomatic treatment only. 
https://en.wikipedia.org/wiki/Systemic_scleroderma http://patient.info/doctor/systemic-sclerosis-scleroderma 
Scleroderma    
(Patient Support Groups) 
• The Juvenile Scleroderma Network is an organization dedicated 
to provide emotional support and educational information to 
parents and their children living with juvenile scleroderma. 
• In the US, the Scleroderma Research Foundation is dedicated to 
raise awareness of the disease and assist those who are affected. 
• The Scleroderma Society is a UK charity founded in 1982 to 
provide support for both people with scleroderma and their 
families. 
https://en.wikipedia.org/wiki/Systemic_scleroderma 
Sjögren syndrome    
(Definition) 
Sjögren syndrome (Sjögren's syndrome (SS)) is a systemic 
chronic autoimmune inflammatory disorder characterized by 
lymphocytic infiltrates in exocrine organs with sicca 
symptoms, such as xerophthalmia (dry eyes), xerostomia 
(dry mouth), and parotid gland enlargement.  
 
http://emedicine.medscape.com/article/332125-overview 
Sjögren syndrome     
(Glandular Manifestations) 
• Sjögren syndrome typically presents as dry eyes and dry mouth, also 
referred to as xerophthalmia (or keratoconjunctivitis sicca) and 
xerostomia, respectively. 
• Eye symptoms include dryness, grittiness, pruritus, and foreign body 
sensation.  
• Oral symptoms include difficulty speaking, eating, or swallowing, and 
frequent sips of water may be needed. 
• The patient’s eye may show conjunctival injection . 
• Early oral findings include decreased salivary pool and dry mucous 
membranes, which can progress to erythema, fissuring, and ulceration. 
• The patient may also have multiple dental caries as a result of 
decreased salivary flow. 
• Parotid glands may be tender or swollen.   
http://www.aafp.org/afp/2009/0315/p465.html 
Sjögren syndrome     
(Extraglandular Manifestations) 
• Arthralgia or nonerosive arthritis characterized by tenderness, swelling, or 
effusion of peripheral joints. 
• Gastrointestinal symptoms (reflux, dyspepsia, diarrhea, constipation). 
• Autoimmune thyroiditis. 
• Pulmonary disease (chronic cough, recurrent bronchitis with chronic diffuse 
interstitial infiltrates on radiography, abnormal spirometry, pulmonary 
alveolitis or fibrosis on computed tomography). 
• Raynaud’s phenomenon. 
• Cutaneous vasculitis. 
• Peripheral neuropathy. 
• Lymphadenopathy (enlarged lymph nodes in cervical, axillary, or inguinal 
region). 
• Renal involvement (proteinuria, renal tubular acidosis, interstitial nephritis, 
glomerulonephritis, abnormal urinalysis). 
• Fever not associated with infectious process. 
 
http://www.aafp.org/afp/2009/0315/p465.html 
Sjögren syndrome     
(Dry Eyes) 
http://www.rheum-care.com/wp-content/uploads/2014/05/stock-photo-16982142-blood-capillary-human-eye.jpg 
Sjögren syndrome     
(Dry Mouth) 
http://1.bp.blogspot.com/_PUjYKIyEP6g/TLvbsvFVfYI/AAAAAAAADTI/WZ0pX1oMZys/s640/nyc-dentist-blog-dry-mouth.jpg 
Sjögren syndrome     
(Arthritis ) 
http://www.healthline.com/hlcmsresource/images/slideshow/secondary-sjogrens-syndrome-and-arthritis/285x285_Secondary_Sjogrens_Syndrome_And_Arthritis_Doctor_9.jpg 
Sjögren syndrome     
(Pulmonary Fibrosis) 
http://www.radiologyassistant.nl/data/bin/w440/a5097977c62e89_sarc-fibrosis.jpg 
Sjögren syndrome     
(Raynaud’s Phenomenon) 
http://userfiles.steadyhealth.com/userfiles/articles/thumb_raynaud-syndrome.jpg 
Sjögren syndrome     
(Lymphadenopathy) 
http://www.antimicrobe.org/images-Monographs/e27_TB_1.jpg 
Sjögren syndrome     
(Diagnostic Testing: Eye Symptoms ) 
• Eye symptoms are usually evaluated with the Schirmer test or 
the rose bengal test.  
• The Schirmer test involves placing a sterile filter paper strip 
beneath the lower eyelid for five minutes. If the moistened area 
measures less than 5 mm, the test is positive.  
• The rose bengal test usually is performed by an ophthalmologist; 
1% rose bengal dye is instilled and the ocular surface integrity is 
evaluated by quantitatively scoring the staining of the 
conjunctiva.  Rose bengal dye will stain devitalized corneal and 
conjunctival epithelial cells. The test will identify keratosclerosis 
(KCS) when minimal ocular symptoms are present. A routine slit-
lamp evaluation can identify a diminished tear meniscus.  
http://www.aafp.org/afp/2009/0315/p465.html 
Sjögren syndrome     
(Diagnostic Testing: Oral Dryness) 
• Oral dryness can be evaluated objectively by nonstimulated 
whole saliva flow collection, in which the patient spits into a 
graduated test tube every minute for 15 minutes.  Collection of 
less than 1.5 mL in 15 minutes is considered a positive result.  
• Other tests include contrast sialography, which visualizes the 
salivary glands and ducts via contrast dye injection into the 
Stensen duct, and scintigraphy, which evaluates salivary gland 
function by measuring sequential uptake and excretion of 
technetium 99m.  
http://www.aafp.org/afp/2009/0315/p465.html 
Sjögren syndrome     
(Diagnostic Testing: Biopsy) 
• Although once considered the gold standard for diagnosis of 
Sjögren syndrome, minor salivary gland biopsy of tissue taken 
from the patient’s lip is not always necessary. 
• A positive biopsy is defined as at least one focus of dense, 
inflammatory infiltrate containing at least 50 lymphocytes per 4 
mm2. 
• The lip biopsy may be useful in ambiguous cases or when 
therapy beyond symptom management is being considered. 
http://www.aafp.org/afp/2009/0315/p465.html 
Sjögren syndrome     
(Patient education) 
• Neither a cure nor a specific treatment is known to permanently 
restore gland secretion. Instead, treatment is generally symptomatic 
and supportive. 
• Eye care: moisture replacement (artificial tears), goggles, 
cyclosporine, cevimeline, and pilocarpine.  
• Vaginal dryness: personal lubricants. 
• Musculoskeletal: nonsteroidal anti-inflammatory drugs (NSAIDs), 
corticosteroids, intravenous immunoglobulin), disease-modifying 
antirheumatic drugs (DMARDs). 
• Systemic: biologic disease-modifying antirheumatic drugs (DMARDs). 
• Dental care: topical fluoride application to strengthen tooth enamel 
and frequent teeth cleanings by a dental hygienist.   
https://en.wikipedia.org/wiki/Sj%C3%B6gren%27s_syndrome#Treatment 
Sjögren syndrome     
(Surgical Therapy) 
• Occlusion of the lacrimal puncta can be corrected 
surgically.  
• Electrocautery and other techniques can be used for 
permanent punctal occlusion. 
• During surgery, the anesthesiologist should administer 
as little anticholinergic medication as possible and use 
humidified oxygen to help avoid inspissation of 
pulmonary secretions.  
• Good postoperative respiratory therapy should also be 
provided.  
• Patients are at higher risk for corneal abrasions, so 
ocular lubricants should be considered. 
http://emedicine.medscape.com/article/332125-treatment#showall 
Sjögren syndrome     
(Patient education) 
Educate patients with Sjögren syndrome on avoidance 
strategies and self-care issues for the treatment of dry 
mouth, eyes, skin, and vagina.  
http://emedicine.medscape.com/article/332125-overview 
Sjögren syndrome     
(American-European Consensus Sjögren Classification 
Criteria: 1) 
 I. Ocular Symptoms (at least one) 
Dry eyes >3 months? 
Foreign body sensation in the eyes? 
Use of artificial tears >3x per day? 
II. Oral Symptoms (at least one) 
Dry mouth >3 months? 
Recurrent or persistently swollen salivary 
glands? 
Need liquids to swallow dry foods? 
III. Ocular Signs (at least one) 
Schirmer's test, (without anesthesia) ≤5 
mm/5 minutes 
Positive vital dye staining (van Bijsterveld 
≥4) 
https://www.sjogrens.org/home/research-programs/healthcare-providers/diagnosis-criteria 
IV. Histopathology Lip biopsy 
showing focal lymphocytic 
sialoadenitis 
     (focus score ≥1 per 4 mm2)2 
 
V. Oral Signs (at least one) 
Unstimulated whole salivary 
flow (≤1.5 mL in 15 minutes) 
Abnormal parotid sialography3 
Abnormal salivary scintigraphy4 
 
VI. Autoantibodies (at least one) 
Anti-SSA (Ro) or Anti-SSB (La) 
Sjögren syndrome     
(American-European Consensus Sjögren 
Classification Criteria: 2) 
For a primary Sjögren diagnosis 
a. Any 4 of the 6 criteria, must 
include either item IV 
(Histopathology) or VI 
(Autoantibodies) 
b. Any 3 of the 4 objective criteria 
(III, IV, V, VI) 
For a secondary Sjögren diagnosis 
https://www.sjogrens.org/home/research-programs/healthcare-providers/diagnosis-criteria 
In patients with another well-defined 
major connective tissue disease, the 
presence of one symptom (I or II) plus 
2 of the 3 objective criteria (III, IV and 
V) is indicative of secondary SS. 
Exclusion Criteria 
Past head and neck radiation treatment, Hepatitis C infection, Acquired 
immunodeficiency syndrome (AIDS), Pre-existing lymphoma, Sarcoidosis, Graft 
versus host disease, Current use of anticholinergic drugs 
Mixed Connective Tissue Disease    
(Definition) 
Mixed connective tissue disease (MTCD), or  undifferentiated 
connective tissue disease  is a rare chronic autoimmune 
inflammatory connective tissue disorder characterized by the 
presence of high titers of a distinctive autoantibody anti-U1 
ribonucleoprotein (RNP) what may be an overlapping group 
of connective tissue disorders (e.g., systemic lupus 
erythematosus, polymyositis, and scleroderma) that cannot 
be diagnosed in more specific terms.   
http://rarediseases.org/rare-diseases/mixed-connective-tissue-disease-mctd/ 
Mixed Connective Tissue Disease    
(Manifestation) 
• MCTD combines features of scleroderma, myositis, systemic 
lupus erythematosus, rheumatoid arthritis, dermatomyositis, 
Raynaud’s phenomenon,  etc. and is thus considered an overlap 
syndrome. 
• In the beginning stages, patients who have MCTD have 
symptoms similar to those of patients with other connective 
tissue disorders, including fatigue, muscle pain with no 
apparent cause, joint fever, Raynaud phenomenon, severe 
polymyositis, intense arthritis, aseptic meningitis, myelitis, 
gangrene,  abdominal pain, neuropathy, hearing loss. 
 
http://my.clevelandclinic.org/health/diseases_conditions/hic_Mixed_Connective_Tissue_Disease 
Mixed Connective Tissue Disease    
(The "classic" symptoms) 
• Raynaud phenomenon. 
• Swollen "sausage-like" fingers, sometimes temporary but at 
other times progressing into sclerodactyly (thin fingers with 
hardened skin and limited movement). 
• Inflamed joints and muscles. 
• Pulmonary hypertension (high blood pressure in the blood 
vessels of the lungs). 
http://my.clevelandclinic.org/health/diseases_conditions/hic_Mixed_Connective_Tissue_Disease 
Mixed Connective Tissue Disease    
(Raynaud Phenomenon) 
http://www.physio-pedia.com/images/3/34/Ray.png 
Mixed Connective Tissue Disease    
(Swollen “Sausage-Like" Fingers) 
http://www.physio-pedia.com/images/7/70/PsAHands.jpg 
Mixed Connective Tissue Disease    
(Inflamed Joints and Muscles) 
http://images.medicinenet.com/images/rheumatoid-arthritis-feet.jpg 
Mixed Connective Tissue Disease    
(Pulmonary hypertension) 
http://www.scielo.br/img/revistas/rb/v41n3/en_12f8.gif 
Mixed Connective Tissue Disease    
(Alarcon-Segovia Diagnostic Criteria) 
• Serological criteria: Positive anti U1 RNP at hemagglutination titer 
>1:1600 
• 2. Clinical criteria: 
• Oedema of hands 
• Synovitis 
• Myositis 
• Raynaud´s 
• Acrosclerosis 
• Requirements: 
• Serological 
• At least 3 clinical features 
• Association of hand oedema, Raynaud´s and acrosclerosis requires at 
least one other feature 
http://www.medicalcriteria.com/criteria/reu_mctd.htm 
Mixed Connective Tissue Disease    
(Kusukawa Diagnostic Criteria) 
• Common Symptoms 
• Reynaud´s Phenomenon 
• Swollen fingers or hands 
• Presence of Anti U1 RNP 
• Mixed findings 
• A. SLE like 
• Polyarthritis 
• Pericarditis/pleuritis 
• Lymphadenopathy 
• Facial erithema 
• Leucopenia/thrombocytopenia 
• B. Scleroderma like 
• Sclerodactyly 
• Pulmonary fibrosis 
• Esophageal dysmotility 
• C. Polymyositis like 
• Muscle weakness 
• High creatine phosphokinase 
(CPK) 
• Myophatic electromyogram 
(EMG) 
http://www.medicalcriteria.com/criteria/reu_mctd.htm 
Requirement for diagnosis: At least one common symptom, with positive U1 RNP 
antibodies and one or more findings in at least two of the three categories A, B, and C. 
Mixed Connective Tissue Disease    
(Standard Therapies) 
• The treatment is based upon the specific symptoms present in each 
case.  
• Many of the manifestations of MCTD appear to respond to therapy 
with corticosteroids such as prednisone.  
• Mild forms appear to be controlled by nonsteroidal anti-inflammatory 
drugs (NSAIDs) or low doses of corticosteroids. When more severe 
involvement of major organs occurs, larger doses of corticosteroids 
may be of benefit.   
• In some cases, drugs that suppress the immune system (e.g. disease-
modifying antirheumatic drugs) have been used to treat individuals 
with MCTD. 
• Calcium channel blockers may be used to treat Raynaud's 
phenomenon. 
• Bosentan or sildenafil may be used to treat Pulmonary 
hypertension.  
 
http://www.medicalcriteria.com/criteria/reu_mctd.htm 
Prognosis  
• The prognosis for patients who have SCTD is different for 
different diseases and varies from a benign course to severe 
progressive course. 
• There are many possible outcomes, depending on the organs 
affected, the degree of inflammation, and how quickly the 
disease progresses.  
• In approximately one third of patients the clinical symptoms go 
into long-term remission. 
• One third of patients have a severe, progressive SCTD course.  
• Persistent morbidity often is attributable to arthritis, easy 
fatiguability, and dyspnea on exertion.  
• Most deaths from SCTD are due to heart failure caused by 
pulmonary arterial hypertension (PAH). 
http://www.ncbi.nlm.nih.gov/pubmed/16084324 
Prophylaxis 
• Since the causes of SCTD are not known, there is no way of 
preventing these diseases, however, lifestyle and 
environmental factors if modified could assist in it.   
• Progression some forms of SCTD could be prevented if 
treated aggressively prior to manifestations of symptoms, 
however, if such is the case, criteria would have to be 
determined for patient selection for this preventive 
treatment, and only those patients whose probability to 
develop clinical disease exceeds the established threshold, 
should be treated while asymptomatic. 
http://www.arc.org.uk/arthinfo/medpubs/6529/6529.asp 
Abbreviations  
ACE – angiotensin converting 
enzyme  
AIDS - Acquired immunodeficiency  
ANA  - antinuclear antibody  
syndrome  
anti-ENA - anti-extractable nuclear 
antigen 
ARBs - angiotensin II receptor 
antagonists  
CPK - creatine phosphokinase  
DIP - distal interphalangeal joints 
DMARDs - disease-modifying 
antirheumatic drugs  
dsDNA - anti-double stranded DNA 
antibodies  
EMG - myophatic electromyogram  
EULAR - European League Against 
Rheumatism  
 
KCS - keratosclerosis 
LE - lupus erythematosus   
MCP - metacarpophalangeal joints 
MCTD - Mixed Connective Tissue Disease  
MFS - Marfan syndrome 
NSAIDS - nonsteroidal anti-inflammatory 
drugs  
PAH - pulmonary arterial hypertension 
PIP - proximal interphalangeal joints 
RNP - anti-U1 ribonucleoprotein  
SCTD - systemic connective tissue diseases 
SS - Sjögren's syndrome  
SSc - systemic sclerosis  
VEDOSS - Very Early Diagnosis Of GI - 
gastrointestinal  
Diagnostic and treatment guidelines 
Marfan Syndrome 
Medical Management of Marfan Syndrome 
MARFAN DX: A Diagnostic Tool for Healthcare Professionals 
Systemic Lupus Erythematosus (SLE) Treatment & Management 
Systemic Lupus Erythematosus: Pathogenesis 20 and Clinical 
Features  
Guidelines for clinical trials in systemic sclerosis (scleroderma) 
Systemic Sclerosis 
Diagnosis and Management of Sjögren Syndrome 
Sjogren Syndrome Treatment & Management 
Mixed Connective Tissue Disease 
 
 
